COPD and Mucolytics- PEACE Trial

World COPD Day in China

Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation, and has many components including mucus hypersecretion, oxidative stress, and airway inflammation. Most patients remain symptomatic and treatment with long-acting inhaled anticholinergic agents or β agonists, alone or with inhaled corticosteroids, improves lung function and health status while reducing risk of exacerbation and probably decreasing risk of death . In this study published in Lancet authors looked at carbocisteine, a mucolytic agent with anti-inflammatory and antioxidation activities, could reduce the yearly exacerbation rate in patients with COPD. This drug is not used because not recommended by GOLD guidelines. Primary end point was exacerbation rate at one yaer. Also looked at Quality of life was assessed by St George’s Respiratory Questionnaire (SGRQ) scores. Read More...

You can read comments from the same journal.